1
|
Solea AB, Demirci G, Harvey FM, Crochet A, Zobi F, Mamula Steiner O. The role of stereochemistry in the anticancer activity of Re(I) tricarbonyl complexes. Dalton Trans 2024; 53:13743-13755. [PMID: 39021254 DOI: 10.1039/d4dt01643b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/20/2024]
Abstract
Cancer is a leading cause of death worldwide, accounting for about one among six deaths, so the quest for new and improved therapies is of crucial importance. The discovery of cisplatin as an anticancer agent has paved the way for the development of other metal-based therapeutic agents and Re(I)-based candidates have been recently found to show promising results. It is known as well that chirality plays a central role in the interactions of metal-based drugs with intrinsically chiral biomolecules such as membrane transport proteins or DNA. To further exploit this property, we have developed a series of diastereomeric dinuclear Re(I) complexes with chiral ligands containing pinene-bipyridine units. These complexes offer unique insights into the relation between stereochemistry and biological activity. Single-crystal X-ray diffraction studies, spectroscopic analysis, including UV-Vis and circular dichroism (CD), confirmed the chiral structures of these complexes. Biological activity assessments were carried out against various cancer cell lines, with a particular focus on breast and colon cancer. The diastereomers exhibited distinct anticancer activities, with some displaying promising results. Notably, one diastereomer showed exceptional cytotoxicity against HCT116 and MCF-7 cancer cells. This research underscores the significance of chirality in the design of novel anticancer agents, providing insights into the potential of dinuclear Re(I) complexes as effective candidates for cancer treatment.
Collapse
Affiliation(s)
- Atena B Solea
- University of Applied Sciences of Western Switzerland, HES-SO, HEIA-FR, Pérolles 80, CH-1705 Fribourg, Switzerland.
| | - Gozde Demirci
- University of Fribourg, Department of Chemistry, Chemin du Musée 9, CH-1700 Fribourg, Switzerland
| | - Freya M Harvey
- University of Applied Sciences of Western Switzerland, HES-SO, HEIA-FR, Pérolles 80, CH-1705 Fribourg, Switzerland.
| | - Aurelien Crochet
- University of Fribourg, Department of Chemistry, Chemin du Musée 9, CH-1700 Fribourg, Switzerland
| | - Fabio Zobi
- University of Fribourg, Department of Chemistry, Chemin du Musée 9, CH-1700 Fribourg, Switzerland
| | - Olimpia Mamula Steiner
- University of Applied Sciences of Western Switzerland, HES-SO, HEIA-FR, Pérolles 80, CH-1705 Fribourg, Switzerland.
| |
Collapse
|
2
|
Dürig J, Calcagni M, Buschmann J. Transition metals in angiogenesis - A narrative review. Mater Today Bio 2023; 22:100757. [PMID: 37593220 PMCID: PMC10430620 DOI: 10.1016/j.mtbio.2023.100757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 07/14/2023] [Accepted: 07/31/2023] [Indexed: 08/19/2023] Open
Abstract
The aim of this paper is to offer a narrative review of the literature regarding the influence of transition metals on angiogenesis, excluding lanthanides and actinides. To our knowledge there are not any reviews up to date offering such a summary, which inclined us to write this paper. Angiogenesis describes the process of blood vessel formation, which is an essential requirement for human growth and development. When the complex interplay between pro- and antiangiogenic mediators falls out of balance, angiogenesis can quickly become harmful. As it is so fundamental, both its inhibition and enhancement take part in various diseases, making it a target for therapeutic treatments. Current methods come with limitations, therefore, novel agents are constantly being researched, with metal agents offering promising results. Various transition metals have already been investigated in-depth, with studies indicating both pro- and antiangiogenic properties, respectively. The transition metals are being applied in various formulations, such as nanoparticles, complexes, or scaffold materials. Albeit the increasing attention this field is receiving, there remain many unanswered questions, mostly regarding the molecular mechanisms behind the observed effects. Notably, approximately half of all the transition metals have not yet been investigated regarding potential angiogenic effects. Considering the promising results which have already been established, it should be of great interest to begin investigating the remaining elements whilst also further analyzing the established effects.
Collapse
Affiliation(s)
- Johannes Dürig
- University of Zürich, Faculty of Medicine, Pestalozzistrasse 3, 8032, Zurich, Switzerland
- University Hospital of Zürich, Department of Plastic Surgery and Hand Surgery, Rämistrasse 100, 8091, Zürich, Switzerland
| | - Maurizio Calcagni
- University Hospital of Zürich, Department of Plastic Surgery and Hand Surgery, Rämistrasse 100, 8091, Zürich, Switzerland
| | - Johanna Buschmann
- University Hospital of Zürich, Department of Plastic Surgery and Hand Surgery, Rämistrasse 100, 8091, Zürich, Switzerland
| |
Collapse
|
3
|
Nasiri Sovari S, Kolly I, Schindler K, Djuric A, Srdic-Rajic T, Crochet A, Pavic A, Zobi F. Synthesis, characterization, and in vivo evaluation of the anticancer activity of a series of 5- and 6-(halomethyl)-2,2'-bipyridine rhenium tricarbonyl complexes. Dalton Trans 2023; 52:6934-6944. [PMID: 36916301 DOI: 10.1039/d2dt04041g] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
Abstract
We report the synthesis, characterization, and in vivo evaluation of the anticancer activity of a series of 5- and 6-(halomethyl)-2,2'-bipyridine rhenium tricarbonyl complexes. The study was promoted in order to understand if the presence and position of a reactive halomethyl substituent on the diimine ligand system of fac-[Re(CO)3]+ species may be a key molecular feature for the design of active and non-toxic anticancer agents. Only compounds potentially able to undergo ligand-based alkylating reactions show significant antiproliferative activity against colorectal and pancreatic cell lines. Of the new species presented in this study, one compound (5-(chloromethyl)-2,2'-bipyridine derivative) shows significant inhibition of pancreatic tumour growth in vivo in zebrafish-Panc-1 xenografts. The complex is noticeably effective at 8 μM concentration, lower than its in vitro IC50 values, being also capable of inhibiting in vivo cancer cells dissemination.
Collapse
Affiliation(s)
- Sara Nasiri Sovari
- Department of Chemistry, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland.
| | - Isabelle Kolly
- Department of Chemistry, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland.
| | - Kevin Schindler
- Department of Chemistry, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland.
| | - Ana Djuric
- Department of experimental oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Beograd, Republic of Serbia
| | - Tatjana Srdic-Rajic
- Department of experimental oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Beograd, Republic of Serbia
| | - Aurelien Crochet
- Department of Chemistry, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland.
| | - Aleksandar Pavic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Republic of Serbia.
| | - Fabio Zobi
- Department of Chemistry, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland.
| |
Collapse
|
4
|
Rhenium(I)-tricarbonyl complexes with methimazole and its selenium analogue: Syntheses, characterization and cell toxicity. J Inorg Biochem 2023; 240:112092. [PMID: 36549168 DOI: 10.1016/j.jinorgbio.2022.112092] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 11/24/2022] [Accepted: 12/02/2022] [Indexed: 12/12/2022]
Abstract
This study explores the effect of a thione/selone ligand on the cell toxicity (in vitro) and light activity of diimine Re(CO)3+ complexes. Six rhenium(I) complexes with general formula fac-[Re(CO)3(N,N')X]+ were prepared, where X = 2-mercapto-1-methylimidazole (methimazole; MMI), and 1-methylimidazole-2-selone (MSeI); N,N' = 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen) and 2,9-dimethyl-1,10-phenanthroline (dmphen). Their triflate salts were characterized using single-crystal X-ray diffraction, 1H, 13C and 2D NMR, UV-vis and vibrational spectroscopy. Their cytotoxic properties were tested, showing significant cytotoxicity (IC50 = 8.0-55 μM) towards the human breast cancer cell line MDA-MB-231. The half-inhibitory concentration (IC50) for fac-[Re(CO)3(dmphen)(MMI)]+, the most toxic complex in this series (8.0 ± 0.2 μM), was comparable to that of the corresponding aqua complex fac-[Re(CO)3(dmphen)(H2O)]+ with IC50 = 6.0 ± 0.1 μM. The fac-[Re(CO)3(bpy)(MMI/MSeI)]+ complexes were somewhat less toxic towards the human embryonic kidney cell line HEK-293 T after 48 h of exposure. The stability of the complexes upon irradiation was monitored using UV-vis spectroscopy, with no CO released when exposed to UV-A light (λ = 365 nm).
Collapse
|
5
|
Matlou ML, Malan FP, Nkadimeng S, McGaw L, Tembu VJ, Manicum ALE. Exploring the in vitro anticancer activities of Re(I) picolinic acid and its fluorinated complex derivatives on lung cancer cells: a structural study. J Biol Inorg Chem 2023; 28:29-41. [PMID: 36463538 DOI: 10.1007/s00775-022-01971-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 10/04/2022] [Indexed: 12/07/2022]
Abstract
Fifteen rhenium(I) tricarbonyl complexes of the form fac-[Re(N,O')(CO)3(X)], where N,O'-bidentate ligand = 2-picolinic acid (Pico); 3,5-difluoropyridine-2-carboxylic acid (Dfpc); 3-trifluoromethyl-pyridine-2-carboxylic acid (Tfpc) and X = H2O; pyrazole (Pz); pyridine (Py); imidazole (Im); and methanol (CH3OH) were synthesized using the '2 + 1' mixed ligand approach with an average yield of 84%. The complexes were characterized using the following spectroscopic techniques: IR, 1H and 13C NMR, UV/Vis, and single-crystal X-ray diffraction. The effect of the fluorine atoms on the backbone of the N,O'-bidentate ligand was investigated and a trend was noticed in the carbonyl stretching frequencies: with Pico < Tfpc < Dfpc. The in vitro biological screening on Vero (healthy mammalian), HeLa (cervical carcinoma) and A549 (lung cancer) cells revealed one toxic complex, fac-[Re(Pico)(CO)3(H2O)], with respective LC50 values of 9.0 ± 0.9, 15.8 ± 4.9 (SI = 0.570) and 20.9 ± 0.8 (SI = 0.430) μg/mL. As a result, it can be used as a positive control drug of toxicity.
Collapse
Affiliation(s)
- Mabu L Matlou
- Department of Chemistry, Tshwane University of Technology, P.O. Box X680, Pretoria, 0001, South Africa
| | - Frederick P Malan
- Department of Chemistry, University of Pretoria, 02 Lynnwood Road, Hatfield, Pretoria, 0001, South Africa
| | - Sanah Nkadimeng
- Department of Life and Consumer Sciences, University of South Africa, Private Bag X6, Florida Campus, Florida, 1710, South Africa
| | - Lyndy McGaw
- Phytomedicine Programme, Department of Paraclinical Sciences, University of Pretoria, Private Bag X04, Onderstepoort, 0110, South Africa
| | - Vuyelwa J Tembu
- Department of Chemistry, Tshwane University of Technology, P.O. Box X680, Pretoria, 0001, South Africa
| | - Amanda-Lee E Manicum
- Department of Chemistry, Tshwane University of Technology, P.O. Box X680, Pretoria, 0001, South Africa.
| |
Collapse
|
6
|
Single crystal investigation, spectroscopic, DFT studies, and in-silico molecular docking of the anticancer activities of acetylacetone coordinated Re(I) tricarbonyl complexes. Inorganica Chim Acta 2023. [DOI: 10.1016/j.ica.2022.121335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
7
|
Collery P, Desmaële D, Harikrishnan A, Veena V. Remarkable Effects of a Rhenium(I)-diselenoether Drug on the Production of Cathepsins B and S by Macrophages and their Polarizations. Curr Pharm Des 2023; 29:2396-2407. [PMID: 37859327 DOI: 10.2174/0113816128268963231013074433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Accepted: 09/21/2023] [Indexed: 10/21/2023]
Abstract
BACKGROUND/OBJECTIVE Tumor-associated macrophages (TAMs) produce an excessive amount of cysteine proteases, and we aimed to study the effects of anticancer rhenium(I)-diselenoether (Re-diSe) on the production of cathepsins B and S by macrophages. We investigated the effect of Re-diSe on lipopolysaccharides (LPS) induced M1 macrophages, or by interleukin 6 (IL-6) induced M2 macrophages. METHODS Non-stimulated or prestimulated murine Raw 264 or human THP-1 macrophages were exposed to increasing concentrations of the drug (5, 10, 20, 50 and 100 μM) and viability was assayed by the MTT assay. The amount of cysteine proteases was evaluated by ELISA tests, the number of M1 and M2 macrophages by the expression of CD80 or CD206 biomarkers. The binding of Re-diSe with GSH as a model thiol-containing protein was studied by mass spectrometry. RESULTS A dose-dependent decrease in cathepsins B and S was observed in M1 macrophages. There was no effect in non-stimulated cells. The drug induced a dramatic dose-dependent increase in M1 expression in both cells, significantly decreased the M2 expression in Raw 264 and had no effect in non-stimulated macrophages. The binding of the Re atom with the thiols was clearly demonstrated. CONCLUSION The increase in the number of M1 and a decrease in M2 macrophages treated by Re-diSe could be related to the decrease in cysteine proteases upon binding of their thiol residues with the Re atom.
Collapse
Affiliation(s)
- Philippe Collery
- Society for the Coordination of Therapeutic Researches, 20220 Algajola, France
| | - Didier Desmaële
- Department of Chemistry, Institut Galien, Université Paris-Saclay, 91400 Orsay, France
| | - Adhikesavan Harikrishnan
- Department of Chemistry, School of Arts and Science, Vinayaka Mission Research Foundation- AV Campus, Chennai 560064, India
| | - Vijay Veena
- School of Allied Healthcare and Sciences, Jain University, Bangalore 560066, India
| |
Collapse
|
8
|
Polypyridyl coordinated rhenium(I) tricarbonyl complexes as model devices for cancer diagnosis and treatment. Polyhedron 2022. [DOI: 10.1016/j.poly.2022.116178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
9
|
Ramos-Inza S, Plano D, Sanmartín C. Metal-based compounds containing selenium: An appealing approach towards novel therapeutic drugs with anticancer and antimicrobial effects. Eur J Med Chem 2022; 244:114834. [DOI: 10.1016/j.ejmech.2022.114834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 09/22/2022] [Accepted: 10/02/2022] [Indexed: 11/17/2022]
|
10
|
Hao L, Ling YY, Huang ZX, Pan ZY, Tan CP, Mao ZW. Real-time tracking of ER turnover during ERLAD by a rhenium complex via lifetime imaging. Natl Sci Rev 2022; 9:nwab194. [PMID: 35958681 PMCID: PMC9362766 DOI: 10.1093/nsr/nwab194] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Revised: 09/23/2021] [Accepted: 09/23/2021] [Indexed: 11/15/2022] Open
Abstract
Endoplasmic reticulum (ER) degradation by autophagy (ER-phagy) is a recently revealed selective autophagy pathway that plays important roles in organelle turnover and protein degradation, but the biological functions of ER-phagy are largely unknown. Here, we present an ER-targeting Re(I) tricarbonyl complex (Re-ERLAD) that can accumulate in the ER, induce ER-to-lysosome-associated degradation (ERLAD) upon visible light irradiation, and label ER buds and track their morphological alterations during ER-phagy. The emission of Re-ERLAD is sensitive to viscosity, which is a key parameter reflecting the amount of unfolded protein in the ER. Quantitative detection using two-photon fluorescence lifetime imaging microscopy shows that ER viscosity initially increases and then decreases during ERLAD, which reveals that ERLAD is a pathway for alleviating ER stress caused by unfolded proteins. In conclusion, our work presents the first specific photoinducer and tracker of ERLAD, which can be used in studying the regulatory mechanism and function of this process.
Collapse
Affiliation(s)
- Liang Hao
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou 510275, China
| | - Yu-Yi Ling
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou 510275, China
| | - Zhi-Xin Huang
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou 510275, China
| | - Zheng-Yin Pan
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou 510275, China
| | - Cai-Ping Tan
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou 510275, China
| | - Zong-Wan Mao
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou 510275, China
| |
Collapse
|
11
|
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents. Drug Resist Updat 2022; 63:100844. [DOI: 10.1016/j.drup.2022.100844] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
12
|
Pete S, Roy N, Kar B, Paira P. Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy. Coord Chem Rev 2022. [DOI: 10.1016/j.ccr.2022.214462] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
13
|
Collery P, Lagadec P, Krossa I, Cohen C, Antomarchi J, Varlet D, Lucio M, Guigonis JM, Scimeca JC, Schmid-Antomarchi H, Schmid-Alliana A. Relationship between the oxidative status and the tumor growth in transplanted triple-negative 4T1 breast tumor mice after oral administration of rhenium(I)-diselenoether. J Trace Elem Med Biol 2022; 71:126931. [PMID: 35063816 DOI: 10.1016/j.jtemb.2022.126931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 01/12/2022] [Accepted: 01/14/2022] [Indexed: 10/19/2022]
Abstract
BACKGROUND Selective inhibitory effects of rhenium(I)-diselenoether (Re-diSe) were observed in cultured breast malignant cells. They were attributed to a decrease in Reactive Oxygen Species (ROS) production. A concomitant decrease in the production of Transforming Growth Factor-beta (TGFβ1), Insulin Growth Factor 1 (IGF1), and Vascular Endothelial Growth Factor A (VEGFA) by the malignant cells was also observed. AIM The study aimed to investigate the anti-tumor effects of Re-diSe on mice bearing 4T1 breast tumors, an experimental model of triple-negative breast cancer, and correlate them with several biomarkers. MATERIAL AND METHODS 4T1 mammary breast cancer cells were orthotopically inoculated into syngenic BALB/c Jack mice. Different doses of Re-diSe (1, 10, and 60 mg/kg) were administered orally for 23 consecutive days to assess the efficacy and toxicity. The oxidative status was evaluated by assaying Advanced Oxidative Protein Products (AOPP), and by the dinitrophenylhydrazone (DNPH) test in plasma of healthy mice, non-treated tumor-bearing mice (controls), treated tumor-bearing mice, and tumors in all tumor-bearing mice. Tumor necrosis factor (TNFα), VEGFA, VEGFB, TGFβ1, Interferon, and selenoprotein P (selenoP) were selected as biomarkers. RESULTS Doses of 1 and 10 mg/kg did not affect the tumor weights. There was a significant increase in the tumor weights in mice treated with the maximum dose of 60 mg/kg, concomitantly with a significant decrease in AOPP, TNFα, and TGFβ1 in the tumors. SelenoP concentrations increased in the plasma but not in the tumors. CONCLUSION We did not confirm the anti-tumor activity of the Re-diSe compound in this experiment. However, the transplantation of the tumor cells did not induce an expected pro-oxidative status without any increase of the oxidative biomarkers in the plasma of controls compared to healthy mice. This condition could be essential to evaluate the effect of an antioxidant drug. The choice of the experimental model will be primordial to assess the effects of the Re-diSe compound in further studies.
Collapse
Affiliation(s)
- Philippe Collery
- Société de Coordination de Recherches Thérapeutiques, 20220, Algajola, France.
| | - Patricia Lagadec
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Imène Krossa
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Charlotte Cohen
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Julie Antomarchi
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | | | - Marianna Lucio
- Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt, 85764, Neuherberg, Germany
| | - Jean-Marie Guigonis
- Université Nice Sophia Antipolis, Plateforme "Bernard Rossi", UFR de médecine Pasteur, UMR 4320, CEA TIRO, 06107, Nice cedex 2, France
| | - Jean-Claude Scimeca
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Heidy Schmid-Antomarchi
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Annie Schmid-Alliana
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| |
Collapse
|
14
|
Drug combination study of novel oxorhenium(V) complexes. J Inorg Biochem 2022; 231:111807. [DOI: 10.1016/j.jinorgbio.2022.111807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 03/11/2022] [Accepted: 03/21/2022] [Indexed: 11/23/2022]
|
15
|
Schindler K, Zobi F. Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives. Molecules 2022; 27:539. [PMID: 35056856 PMCID: PMC8777860 DOI: 10.3390/molecules27020539] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 12/23/2021] [Accepted: 01/12/2022] [Indexed: 12/20/2022] Open
Abstract
Organometallic compounds are increasingly recognized as promising anticancer and antibiotic drug candidates. Among the transition metal ions investigated for these purposes, rhenium occupies a special role. Its tri- and dicarbonyl complexes, in particular, attract continuous attention due to their relative ease of preparation, stability and unique photophysical and luminescent properties that allow the combination of diagnostic and therapeutic purposes, thereby permitting, e.g., molecules to be tracked within cells. In this review, we discuss the anticancer and antibiotic properties of rhenium tri- and dicarbonyl complexes described in the last seven years, mainly in terms of their structural variations and in vitro efficacy. Given the abundant literature available, the focus is initially directed on tricarbonyl complexes of rhenium. Dicarbonyl species of the metal ion, which are slowly gaining momentum, are discussed in the second part in terms of future perspective for the possible developments in the field.
Collapse
Affiliation(s)
| | - Fabio Zobi
- Department of Chemistry, Fribourg University, Chemin du Musée 9, 1700 Fribourg, Switzerland;
| |
Collapse
|
16
|
Pal M, Wadawale A, Chauhan N, Majumdar A, Subramanian M, Bhuvanesh N, Dey S. Anticancer potential of Pd and Pt metallo-macrocycles of phosphines and 4,4΄-dipyridyldiselenide. Polyhedron 2022. [DOI: 10.1016/j.poly.2021.115547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Sharma S. A, N. V, Kar B, Das U, Paira P. Target-specific mononuclear and binuclear rhenium( i) tricarbonyl complexes as upcoming anticancer drugs. RSC Adv 2022; 12:20264-20295. [PMID: 35919594 PMCID: PMC9281374 DOI: 10.1039/d2ra03434d] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 06/24/2022] [Indexed: 11/21/2022] Open
Abstract
Metal complexes have gradually been attracting interest from researchers worldwide as potential cancer therapeutics. Driven by the many side effects of the popular platinum-based anticancer drug cisplatin, the tireless endeavours of researchers have afforded strategies for the design of appropriate metal complexes with minimal side effects compared to cisplatin and its congeners to limit the unrestricted propagation of cancer. In this regard, transition metal complexes, especially rhenium-based complexes are being identified and highlighted as promising cancer theranostics, which are endowed with the ability to detect and annihilate cancer cells in the body. This is attributed the amazing photophysical properties of rhenium complexes together with their ability to selectively attack different organelles in cancer cells. Therefore, this review presents the properties of different rhenium-based complexes to highlight their recent advances as anticancer agents based on their cytotoxicity results. In this review, rhenium-based complexes are highlighted as promising cancer theranostics, which are endowed with the ability to detect and annihilate cancer cells in the body.![]()
Collapse
Affiliation(s)
- Ajay Sharma S.
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India
| | - Vaibhavi N.
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India
| | - Binoy Kar
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India
| | - Utpal Das
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India
| | - Priyankar Paira
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India
| |
Collapse
|
18
|
Aleksanyan DV, Churusova SG, Brunova VV, Rybalkina EY, Susova OY, Peregudov AS, Klemenkova ZS, Denisov GL, Kozlov VA. Synthesis, characterization, and cytotoxic activity of N-metallated rhenium(I) pincer complexes with (thio)phosphoryl pendant arms. J Organomet Chem 2020. [DOI: 10.1016/j.jorganchem.2020.121498] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
19
|
Liew HS, Mai CW, Zulkefeli M, Madheswaran T, Kiew LV, Delsuc N, Low ML. Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy. Molecules 2020; 25:E4176. [PMID: 32932573 PMCID: PMC7571230 DOI: 10.3390/molecules25184176] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 07/21/2020] [Accepted: 07/23/2020] [Indexed: 02/05/2023] Open
Abstract
Photodynamic therapy (PDT) is emerging as a significant complementary or alternative approach for cancer treatment. PDT drugs act as photosensitisers, which upon using appropriate wavelength light and in the presence of molecular oxygen, can lead to cell death. Herein, we reviewed the general characteristics of the different generation of photosensitisers. We also outlined the emergence of rhenium (Re) and more specifically, Re(I) tricarbonyl complexes as a new generation of metal-based photosensitisers for photodynamic therapy that are of great interest in multidisciplinary research. The photophysical properties and structures of Re(I) complexes discussed in this review are summarised to determine basic features and similarities among the structures that are important for their phototoxic activity and future investigations. We further examined the in vitro and in vivo efficacies of the Re(I) complexes that have been synthesised for anticancer purposes. We also discussed Re(I) complexes in conjunction with the advancement of two-photon PDT, drug combination study, nanomedicine, and photothermal therapy to overcome the limitation of such complexes, which generally absorb short wavelengths.
Collapse
Affiliation(s)
- Hui Shan Liew
- School of Postgraduate Studies, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia;
| | - Chun-Wai Mai
- Centre for Cancer and Stem Cell Research, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia;
- School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia; (M.Z.); (T.M.)
| | - Mohd Zulkefeli
- School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia; (M.Z.); (T.M.)
| | - Thiagarajan Madheswaran
- School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia; (M.Z.); (T.M.)
| | - Lik Voon Kiew
- Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia;
| | - Nicolas Delsuc
- Laboratoire des Biomolécules, Département de Chimie, École Normale Supérieure, PSL University, Sorbonne Université, 75005 Paris, France;
| | - May Lee Low
- School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia; (M.Z.); (T.M.)
| |
Collapse
|
20
|
Capper MS, Packman H, Rehkämper M. Rhenium-Based Complexes and in Vivo Testing: A Brief History. Chembiochem 2020; 21:2111-2115. [PMID: 32196894 PMCID: PMC7496976 DOI: 10.1002/cbic.202000117] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 03/19/2020] [Indexed: 12/12/2022]
Abstract
The success of metal-based anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32/78 cancer regimens, metal-based drugs have a clear role in cancer therapy. Despite this, metal-based anticancer therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metal-based drug candidates such as auranofin, a gold-based drug candidate as well as ruthenium-based candidates, NAMI-A, NKP-1339 and TLD-1433. All are currently undergoing clinical trials. Another class of complexes under study are rhenium-based; such complexes have undergone extensive in vitro testing but only nine have been reported to display antitumour in vivo activity, which is a necessary step before entering clinical trials. This review will document, chronologically, the rhenium-based drug candidates that have undergone in vivo testing and the outlook for such complexes.
Collapse
Affiliation(s)
- Miles S Capper
- Department of Earth Science and Engineering, Imperial College London, Royal School of Mines, Prince Consort Rd, Kensington London, SW7 2AZ, UK
| | - Hollie Packman
- Department of Earth Science and Engineering, Imperial College London, Royal School of Mines, Prince Consort Rd, Kensington London, SW7 2AZ, UK
| | - Mark Rehkämper
- Department of Earth Science and Engineering, Imperial College London, Royal School of Mines, Prince Consort Rd, Kensington London, SW7 2AZ, UK
| |
Collapse
|
21
|
Marker SC, King AP, Granja S, Vaughn B, Woods JJ, Boros E, Wilson JJ. Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes. Inorg Chem 2020; 59:10285-10303. [PMID: 32633531 PMCID: PMC8114230 DOI: 10.1021/acs.inorgchem.0c01442] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The established platinum-based drugs form covalent DNA adducts to elicit their cytotoxic response. Although they are widely employed, these agents cause toxic side-effects and are susceptible to cancer-resistance mechanisms. To overcome these limitations, alternative metal complexes containing the rhenium(I) tricarbonyl core have been explored as anticancer agents. Based on a previous study ( Chem. Eur. J. 2019, 25, 9206), a series of highly active tricarbonyl rhenium isonitrile polypyridyl (TRIP) complexes of the general formula fac-[Re(CO)3(NN)(ICN)]+, where NN is a chelating diimine and ICN is an isonitrile ligand, that induce endoplasmic reticulum (ER) stress via activation of the unfolded protein response (UPR) pathway are investigated. A total of 11 of these TRIP complexes were synthesized, modifying both the equatorial polypyridyl and axial isonitrile ligands. Complexes with more electron-donating equatorial ligands were found to have greater anticancer activity, whereas the axial ICN ligands had a smaller effect on their overall potency. All 11 TRIP derivatives trigger a similar phenotype that is characterized by their abilities to induce ER stress and activate the UPR. Lastly, we explored the in vivo efficacy of one of the most potent complexes, fac-[Re(CO)3(dmphen)(ptolICN)]+ (TRIP-1a), where dmphen = 2,9-dimethyl-1,10-phenanthroline and ptolICN = para-tolyl isonitrile, in mice. The 99mTc congener of TRIP-1a was synthesized, and its biodistribution in BALB/c mice was investigated in comparison to the parent Re complex. The results illustrate that both complexes have similar biodistribution patterns, suggesting that 99mTc analogues of these TRIP complexes can be used as diagnostic partner agents. The in vivo antitumor activity of TRIP-1a was then investigated in NSG mice bearing A2780 ovarian cancer xenografts. When administered at a dose of 20 mg/kg twice weekly, this complex was able to inhibit tumor growth and prolong mouse survival by 150% compared to the vehicle control cohort.
Collapse
Affiliation(s)
- Sierra C. Marker
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - A. Paden King
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - Samantha Granja
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - Brett Vaughn
- Department of Chemistry, Stony Brook University, Stony Brook, New York, 11794, United States
| | - Joshua J. Woods
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
- Robert F. Smith School for Chemical and Biomolecular Engineering, Cornell, University, Ithaca, New York 14853, United States
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, Stony Brook, New York, 11794, United States
| | - Justin J. Wilson
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| |
Collapse
|
22
|
Delasoie J, Pavic A, Voutier N, Vojnovic S, Crochet A, Nikodinovic-Runic J, Zobi F. Identification of novel potent and non-toxic anticancer, anti-angiogenic and antimetastatic rhenium complexes against colorectal carcinoma. Eur J Med Chem 2020; 204:112583. [PMID: 32731186 DOI: 10.1016/j.ejmech.2020.112583] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 06/06/2020] [Accepted: 06/14/2020] [Indexed: 12/26/2022]
Abstract
Combination therapy targeting both tumor growth and vascularization is considered to be a cornerstone for colorectal carcinomas (CRC) treatment. However, the major obstacles of most clinical anticancer drugs are their weak selective activity towards cancer cells and inherent inner organs toxicity, accompanied with fast drug resistance development. In our effort to discover novel selective and non-toxic agents effective against CRC, we designed, synthesized and characterized a series of rhenium(I) tricarbonyl-based complexes with increased lipophilicity. Two of these novel compounds were discovered to possess remarkable anticancer, anti-angiogenic and antimetastatic activity in vivo (zebrafish-human HCT-116 xenograft model), being effective at very low doses (1-3 μM). At doses as high as 250 μM the complexes did not provoke toxicity issues encountered in clinical anticancer drugs (cardio-, hepato-, and myelotoxicity). In vivo assays showed that the two compounds exceed the anti-tumor and anti-angiogenic activity of clinical drugs cisplatin and sunitinib malate, and display a large therapeutic window.
Collapse
Affiliation(s)
- Joachim Delasoie
- Department of Chemistry, Fribourg University, Chemin Du Musée 9, 1700, Fribourg, Switzerland
| | - Aleksandar Pavic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 152, Belgrade, Republic of Serbia.
| | - Noémie Voutier
- Department of Chemistry, Fribourg University, Chemin Du Musée 9, 1700, Fribourg, Switzerland
| | - Sandra Vojnovic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 152, Belgrade, Republic of Serbia
| | - Aurelien Crochet
- Department of Chemistry, Fribourg University, Chemin Du Musée 9, 1700, Fribourg, Switzerland
| | - Jasmina Nikodinovic-Runic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 152, Belgrade, Republic of Serbia.
| | - Fabio Zobi
- Department of Chemistry, Fribourg University, Chemin Du Musée 9, 1700, Fribourg, Switzerland.
| |
Collapse
|
23
|
Collery P, Desmaele D, Vijaykumar V. Design of Rhenium Compounds in Targeted Anticancer Therapeutics. Curr Pharm Des 2019; 25:3306-3322. [DOI: 10.2174/1381612825666190902161400] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 08/30/2019] [Indexed: 12/25/2022]
Abstract
Background:
Many rhenium (Re) complexes with potential anticancer properties have been synthesized
in the recent years with the aim to overcome the clinical limitations of platinum agents. Re(I) tricarbonyl
complexes are the most common but Re compounds with higher oxidation states have also been investigated, as
well as hetero-metallic complexes and Re-loaded self-assembling devices. Many of these compounds display
promising cytotoxic and phototoxic properties against malignant cells but all Re compounds are still at the stage
of preclinical studies.
Methods:
The present review focused on the rhenium based cancer drugs that were in preclinical and clinical
trials were examined critically. The detailed targeted interactions and experimental evidences of Re compounds
reported by the patentable and non-patentable research findings used to write this review.
Results:
In the present review, we described the most recent and promising rhenium compounds focusing on their
potential mechanism of action including, phototoxicity, DNA binding, mitochondrial effects, oxidative stress
regulation or enzyme inhibition. Many ligands have been described that modulating the lipophilicity, the luminescent
properties, the cellular uptake, the biodistribution, and the cytotoxicity, the pharmacological and toxicological
profile.
Conclusion:
Re-based anticancer drugs can also be used in targeted therapies by coupling to a variety of biologically
relevant targeting molecules. On the other hand, combination with conventional cytotoxic molecules, such
as doxorubicin, allowed to take into profit the targeting properties of Re for example toward mitochondria.
Through the example of the diseleno-Re complex, we showed that the main target could be the oxidative status,
with a down-stream regulation of signaling pathways, and further on selective cell death of cancer cells versus
normal cells.
Collapse
Affiliation(s)
- Philippe Collery
- Society for the Coordination of Therapeutic Researches, 20220 Algajola, France
| | - Didier Desmaele
- Institut Galien, Universite Paris-Saclay, 92296 Chatenay-Malabry, France
| | - Veena Vijaykumar
- Biotechnology Department, REVA University, Bangalore, 560064, India
| |
Collapse
|
24
|
Bauer EB, Haase AA, Reich RM, Crans DC, Kühn FE. Organometallic and coordination rhenium compounds and their potential in cancer therapy. Coord Chem Rev 2019. [DOI: 10.1016/j.ccr.2019.04.014] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
25
|
Konkankit CC, King AP, Knopf KM, Southard TL, Wilson JJ. In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex. ACS Med Chem Lett 2019; 10:822-827. [PMID: 31098006 DOI: 10.1021/acsmedchemlett.9b00128] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 04/16/2019] [Indexed: 12/22/2022] Open
Abstract
The rhenium(I) complex fac-[Re(CO)3(2,9-dimethyl-1,10-phenanthroline)(OH2)]+ (1) was previously shown to exhibit potent in vitro anticancer activity in a manner distinct from conventional platinum-based drugs (J. Am. Chem. Soc. 2017, 139, 14302-14314). In this study, we report further efforts to explore its aqueous speciation and antitumor activity. The cellular uptake of 1 was measured in A2780 and cisplatin-resistant A2780CP70 ovarian cancer cells by inductively coupled plasma mass spectrometry, revealing similar uptake efficiency in both cell lines. High accumulation in the mitochondria was observed, contradicting prior fluorescence microscopy studies. The luminescence of 1 is highly dependent on pH and coordination environment, making fluorescence microscopy somewhat unreliable for determining compound localization. The in vivo anticancer activity of 1 was evaluated in mice bearing patient-derived ovarian cancer tumor xenografts. These studies conclusively show that 1 is capable of inhibiting tumor growth, providing further credibility for the use of these compounds as anticancer agents.
Collapse
Affiliation(s)
- Chilaluck C. Konkankit
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - A. Paden King
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - Kevin M. Knopf
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - Teresa L. Southard
- Department of Biomedical Sciences, Cornell University, Ithaca, New York 14853, United States
| | - Justin J. Wilson
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| |
Collapse
|
26
|
The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers. Invest New Drugs 2019; 37:973-983. [PMID: 30632005 DOI: 10.1007/s10637-019-00727-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Accepted: 01/04/2019] [Indexed: 12/20/2022]
Abstract
The rhenium(I)-diselenoether complex (Re-diSe) is a rhenium tricarbonyl-based drug chelated by a diselenoether ligand. In this work, we compared its inhibitory effects on the hormone-independent MDA-MB231cancer line and other different cancer cell lines after an exposure time of 72 h by MTT assays. The sensitivity of MDA-MB231 was in the same range than the hormone-dependent MCF-7 breast cancer, the PC-3 prostate and HT-29 colon cancer cells, while the A549 lung and the HeLa uterine cancer cells were less sensitive. We compared the inhibitory effects of Re-diSe and of its diselenide ligand (di-Se) on MDA-MB231 and a normal HEK-293 human embryonic cell line, after 72 h and 120 h of exposure. The cytotoxicity was also studied by flow cytometry using ethidium bromide assays, as well as the effects on the ROS production by DFCA-test, while the levels of TGF-β1, VEGF-A, IGF-1 were addressed by ELISA tests. The dose required to inhibit 50% of the proliferation (IC50) of MDA-MB231 breast cancer cells decreased with the time of exposure to 120 h, while the free ligand (di-Se) was found poorly active, demonstrating the important role of Re in this Re-diSe combination. The cytotoxic effects of Re-diSe were highly selective for cancer cells, with a significant increase of the number of dead cancer cells at 5 μM for an exposure time of 120 h, while normal cells were not affected. A remarkable and significant decrease of the production of ROS together with a decrease of VEGF-A, TGF-β1, and IGF-1 by the cancer cells were also observed when cancer cells were exposed to Re-diSe.
Collapse
|
27
|
Ghassami E, Varshosaz J, Minaiyan M, Nasirikenari M, Hoseini SM. Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex® Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer. RECENT PATENTS ON NANOTECHNOLOGY 2019; 13:49-58. [PMID: 30488805 DOI: 10.2174/1872210513666181128162403] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2018] [Revised: 10/16/2018] [Accepted: 10/31/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND Docetaxel is a notably efficient anticancer drug administered for several types of malignancies including ovarian cancer. However, various side effects caused either by the nonspecific distribution of the active ingredient or by high contents of Tween 80 and ethanol in the currently marketed formulations, could even deprive the patients of the treatment. OBJECTIVES In the current study, a novel targeted delivery system composed of Ecoflex® polymeric nanoparticles loaded with docetaxel and equipped with HER-2 specific aptamer molecules was evaluated regarding blood and tissue toxicity, and biodistribution. METHOD The tumor-bearing nude mice, achieved by subcutaneous injection of SKOV-3 cells, were divided into four groups treated with normal saline, Taxotere®, targeted docetaxel nanoparticles, and non-targeted docetaxel nanoparticles. Few patents were alos cied in the article. RESULTS According to the results of hematologic evaluations, almost all hematologic parameters were in normal range with no significant difference among the four groups. Histopathological studies revealed that treatment with targeted nanoparticles caused a remarkable reduction in mitosis in tumor sections and overall reduced organ toxicity compared with Taxotere®. The only exception was spleen in which more damage was caused by the nanoparticles. The results of the biodistribution study were also in accordance with pathological assessments, with significantly lower drug concentration in non-tumor tissues, except for spleen, when targeted nanoparticles were used compared with Taxotere®. CONCLUSION These results could evidence the efficiency of the targeted delivery system in concentrating the drug cargo mostly in its site of action leading to the elimination of its adverse effects caused by exposure of other tissues to the cytotoxic agent.
Collapse
Affiliation(s)
- Erfaneh Ghassami
- Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Jaleh Varshosaz
- Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohsen Minaiyan
- Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | - Seyed M Hoseini
- Department of Pathobiology, Islamic Azad University, Babol, Iran
| |
Collapse
|
28
|
Collery P. Strategies for the development of selenium-based anticancer drugs. J Trace Elem Med Biol 2018; 50:498-507. [PMID: 29548612 DOI: 10.1016/j.jtemb.2018.02.024] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Revised: 02/20/2018] [Accepted: 02/26/2018] [Indexed: 02/07/2023]
Abstract
Many experimental models demonstrated that inorganic and organic selenium (Se) compounds may have an anticancer activity. However, large clinical studies failed to demonstrate that Se supplementations may prevent the outcome of cancers. Moreover, there are few randomized trials in cancer patients and there is not yet any Se compound recognized as anticancer drug. There is still a need to develop new Se compounds with new strategies. For that, it may be necessary to consider that Se compounds may have a dual role, either as anti-oxidant or as pro-oxidant. Experimental studies demonstrated that it is as pro-oxidant that Se compounds have anticancer effects, even though cancer cells have a pro-oxidant status. The oxidative status differs according to the type of cancer, the stage of the disease and to other parameters. We propose to adapt the doses of the Se compounds to markers of the oxidative stress, but also to markers of angiogenesis, which is strongly related with the oxidative status. A dual role of Se on angiogenesis has also been noted, either as pro-angiogenesis or as anti-angiogenesis. The objective for the development of new Se compounds, having a great selectivity on cancer cells, could be to try to normalize these oxidative and angiogenic markers in cancer patients, with an individual adaptation of doses.
Collapse
Affiliation(s)
- Philippe Collery
- Society for the Coordination of Therapeutic Researches, 20220 Algajola, France.
| |
Collapse
|
29
|
Tricarbonylrhenium(I) complexes with the N-methylpyridine-2-carbothioamide ligand – Synthesis, characterization and cytotoxicity studies. J Organomet Chem 2018. [DOI: 10.1016/j.jorganchem.2018.04.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
30
|
Lyczko K, Lyczko M, Meczynska-Wielgosz S, Kruszewski M, Mieczkowski J. Tricarbonylrhenium(I) complexes with the N,6-dimethylpyridine-2-carbothioamide ligand: combined experimental and calculation studies. J COORD CHEM 2018. [DOI: 10.1080/00958972.2018.1476686] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
| | - Monika Lyczko
- Institute of Nuclear Chemistry and Technology, Warsaw, Poland
| | | | - Marcin Kruszewski
- Institute of Nuclear Chemistry and Technology, Warsaw, Poland
- Department of Molecular Biology and Translational Research, Institute of Rural Health, Lublin, Poland
- Faculty of Medicine, University of Information Technology and Management, Rzeszów, Poland
| | | |
Collapse
|
31
|
Banerjee HN, Vaughan D, Boston A, Thorne G, Payne G, Sampson J, Manglik V, Olczak P, Powell BV, Winstead A, Shaw R, Mandal SK. The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines. ACTA ACUST UNITED AC 2018; 10. [PMID: 29707104 PMCID: PMC5915335 DOI: 10.4172/1948-5956.1000512] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Purpose Because of the scarcity of suitable brain cancer drugs, researchers are frantically trying to discover novel and highly potent drugs free of side effects and drug-resistance. Rhenium compounds are known to be nontoxic and exhibit no drug resistance. For that reason, we have developed a series of novel rhenium acetylsalicylato (RAC or ASP) complexes to test their cytotoxicity on brain cancer cells. Also we have attempted to explore the DNAbinding properties of these compounds because many drugs either directly or indirectly bind to DNA. Methods We have treated the RAC series compounds on human astrocytoma brain cancer cell lines and rat normal brain astrocyte cells and determined the efficacy of these complexes through in vitro cytotoxicity assay. We carried out the DNA-binding study through UV titrations of a RAC compound with DNA. Also we attempted to determine the planarity of the polypyridyl ligands of the RAC series compounds using DFT calculations. Results RAC6 is more potent than any other RAC series compounds on HTB-12 human astrocytoma cancer cells as well as on Glioblastoma Multiforme D54 cell lines. In fact, The IC-50 value of RAC6 on HTB-12 cancer cells is approximately 2 μM. As expected, the RAC series compounds were not active on normal cells. The DFT calculations on the RAC series compounds were done and suggest that the polypyridyl ligands in the complexes are planar. The UV-titrations of RAC9 with DNA were carried out. It suggests that RAC9 and possibly all RAC series compounds bind to minor grooves of the DNA. Conclusion Because of the very low activity of RAC6 on normal cells and low lC50 value of on astrocytoma (HTB-12) cell lines, it is possible that RAC6 and its derivatives may potentially find application in the treatment of brain cancers. The DFT calculations and UV titrations suggest that RAC series compounds either bind to DNA intercalatively or minor grooves of the DNA or both. However, it is highly premature to make any definite statement in the absence of other techniques.
Collapse
Affiliation(s)
- Hirendra N Banerjee
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Deidre Vaughan
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Ava Boston
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Gabriel Thorne
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Gloria Payne
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Josiah Sampson
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Vinod Manglik
- Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, USA
| | - Pola Olczak
- Department of Chemistry, Morgan State University, Baltimore, MD, USA
| | - Brent V Powell
- Department of Chemistry, Morgan State University, Baltimore, MD, USA
| | - Angela Winstead
- Department of Chemistry, Morgan State University, Baltimore, MD, USA
| | - Roosevelt Shaw
- Department of Chemistry, Morgan State University, Baltimore, MD, USA
| | - Santosh K Mandal
- Department of Chemistry, Morgan State University, Baltimore, MD, USA
| |
Collapse
|
32
|
Ramos LD, da Cruz HM, Morelli Frin KP. Photophysical properties of rhenium(i) complexes and photosensitized generation of singlet oxygen. Photochem Photobiol Sci 2018; 16:459-466. [PMID: 28054064 DOI: 10.1039/c6pp00364h] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
fac-[Re(ampy)(CO)3(NN)]+ complexes (ampy = 2-aminomethylpyridine and NN = 1,10-phenanthroline (phen), and 2,2'-bipyridine (bpy)) were synthesized, purified and characterized by proton nuclear magnetic resonance (1H NMR), UV-visible and Fourier-transformed infrared (FT-IR) spectroscopies, and their photophysical properties were investigated using steady state and time-resolved emission spectroscopies. The electronic absorption spectra exhibit two main absorption bands: the higher energy band, which was assigned to intraligand transition (IL), and the lower energy band assigned to metal-to-ligand charge transfer (MLCT). Both complexes showed emission at room temperature in a CH3CN solution (λmax = 560 nm, ϕ = 0.091, τ = 560 ns for fac-[Re(ampy)(CO)3(phen)]+; λmax = 568 nm, ϕ = 0.024, τ = 100 ns for fac-[Re(ampy)(CO)3(bpy)]+) and rigid media (λmax = 530 nm, τ = 3300 ns for fac-[Re(ampy)(CO)3(phen)]+; λmax = 530 nm, τ = 853 ns for fac-[Re(ampy)(CO)3(bpy)]+) arising from the lowest lying 3MLCTRe→NN excited state. Both complexes along with fac-[Re(L)(CO)3(NN)]+/0 complexes, L = Cl or pyridine, were capable of efficiently photosensitizing the generation of singlet oxygen with quantum yield in the range of 0.59-0.28. These results highlight the potential application of fac-[Re(L)(CO)3(NN)]+/0 complexes in the development of sensitizers for the generation of singlet oxygen.
Collapse
Affiliation(s)
- Luiz Duarte Ramos
- Universidade Federal do ABC - UFABC, Av. dos Estados 5001, Santo Andre, SP, Brazil09210-170.
| | | | | |
Collapse
|
33
|
Konkankit CC, Marker SC, Knopf KM, Wilson JJ. Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. Dalton Trans 2018; 47:9934-9974. [DOI: 10.1039/c8dt01858h] [Citation(s) in RCA: 153] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A summary of recent developments on the anticancer activity of complexes of rhenium, osmium, and iridium is described.
Collapse
Affiliation(s)
| | - Sierra C. Marker
- Department of Chemistry and Chemical Biology
- Cornell University
- Ithaca
- USA
| | - Kevin M. Knopf
- Department of Chemistry and Chemical Biology
- Cornell University
- Ithaca
- USA
| | - Justin J. Wilson
- Department of Chemistry and Chemical Biology
- Cornell University
- Ithaca
- USA
| |
Collapse
|
34
|
Knopf KM, Murphy BL, MacMillan SN, Baskin JM, Barr MP, Boros E, Wilson JJ. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. J Am Chem Soc 2017; 139:14302-14314. [PMID: 28948792 PMCID: PMC8091166 DOI: 10.1021/jacs.7b08640] [Citation(s) in RCA: 136] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Seven rhenium(I) complexes of the general formula fac-[Re(CO)3(NN)(OH2)]+ where NN = 2,2'-bipyridine (8), 4,4'-dimethyl-2,2'-bipyridine (9), 4,4'-dimethoxy-2,2'-bipyridine (10), dimethyl 2,2'-bipyridine-4,4'-dicarboxylate (11), 1,10-phenanthroline (12), 2,9-dimethyl-1,10-phenanthroline (13), or 4,7-diphenyl-1,10-phenanthroline (14), were synthesized and characterized by 1H NMR spectroscopy, IR spectroscopy, mass spectrometry, and X-ray crystallography. With the exception of 11, all complexes exhibited 50% growth inhibitory concentration (IC50) values that were less than 20 μM in HeLa cells, indicating that these compounds represent a new potential class of anticancer agents. Complexes 9, 10, and 13 were as effective in cisplatin-resistant cells as wild-type cells, signifying that they circumvent cisplatin resistance. The mechanism of action of the most potent complex, 13, was explored further by leveraging its intrinsic luminescence properties to determine its intracellular localization. These studies indicated that 13 induces cytoplasmic vacuolization that is lysosomal in nature. Additional in vitro assays indicated that 13 induces cell death without causing an increase in intracellular reactive oxygen species or depolarization of the mitochondrial membrane potential. Further studies revealed that the mode of cell death does not fall into one of the canonical categories such as apoptosis, necrosis, paraptosis, and autophagy, suggesting that a novel mode of action may be operative for this class of rhenium compounds. The in vivo biodistribution and metabolism of complex 13 and its 99mTc analogue 13* were also evaluated in naı̈ve mice. Complexes 13 and 13* exhibited comparable biodistribution profiles with both hepatic and renal excretion. High-performance liquid chromatography inductively coupled plasma mass-spectrometry (HPLC-ICP-MS) analysis of mouse blood plasma and urine postadministration showed considerable metabolic stability of 13, rendering this potent complex suitable for in vivo applications. These studies have shown the biological properties of this class of compounds and demonstrated their potential as promising theranostic anticancer agents that can circumvent cisplatin resistance.
Collapse
Affiliation(s)
- Kevin M. Knopf
- Department of Chemistry & Chemical Biology, Cornell University, Ithaca, NY 14853, USA
| | - Brendan L. Murphy
- Department of Chemistry & Chemical Biology, Cornell University, Ithaca, NY 14853, USA
| | - Samantha N. MacMillan
- Department of Chemistry & Chemical Biology, Cornell University, Ithaca, NY 14853, USA
| | - Jeremy M. Baskin
- Department of Chemistry & Chemical Biology, Cornell University, Ithaca, NY 14853, USA
- Weill Institute for Cell & Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Martin P. Barr
- Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland
| | - Eszter Boros
- A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, 149 13 Street, Suite 2301, Charlestown, MA 02129, USA
| | - Justin J. Wilson
- Department of Chemistry & Chemical Biology, Cornell University, Ithaca, NY 14853, USA
| |
Collapse
|
35
|
Lyczko K. Crystal structure of a second polymorph of tricarbon-yl( N-methyl-pyridine-2-carboxamide-κ 2N1, O)(thio-cyanato-κ N)rhenium(I). Acta Crystallogr E Crystallogr Commun 2016; 72:1386-1389. [PMID: 27746925 PMCID: PMC5050760 DOI: 10.1107/s205698901601389x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Accepted: 08/30/2016] [Indexed: 11/10/2022]
Abstract
A new polymorph of the title compound, [Re(NCS)(C7H8N2O)(CO)3], crystallizing in the space group P21/n, has been obtained and structurally characterized by the experiment and DFT calculations. In this complex, the rhenium(I) cation is octa-hedrally coordinated by three carbonyl groups in a facial configuration, the N,O-bidentate N-methyl-pyridine-2-carboxamide ligand and the N-bonded thio-cyanate anion. Neighbouring mol-ecules are linked into a three-dimensional network by inter-molecular N-H⋯S and C-H⋯S inter-actions.
Collapse
Affiliation(s)
- Krzysztof Lyczko
- Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
| |
Collapse
|
36
|
Zivic N, Bouzrati-Zerelli M, Kermagoret A, Dumur F, Fouassier JP, Gigmes D, Lalevée J. Photocatalysts in Polymerization Reactions. ChemCatChem 2016. [DOI: 10.1002/cctc.201501389] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Nicolas Zivic
- Aix-Marseille Université, CNRS; Institut de Chimie Radicalaire ICR, UMR 7273; F-13397 Marseille France
| | - Mariem Bouzrati-Zerelli
- Institut de Science des Matériaux de Mulhouse IS2 M; UMR CNRS 7361, UHA; 15, rue Jean Starcky 68057 Mulhouse Cedex France
| | - Anthony Kermagoret
- Aix-Marseille Université, CNRS; Institut de Chimie Radicalaire ICR, UMR 7273; F-13397 Marseille France
| | - Frédéric Dumur
- Aix-Marseille Université, CNRS; Institut de Chimie Radicalaire ICR, UMR 7273; F-13397 Marseille France
| | - Jean-Pierre Fouassier
- Institut de Science des Matériaux de Mulhouse IS2 M; UMR CNRS 7361, UHA; 15, rue Jean Starcky 68057 Mulhouse Cedex France
- ENSCMu-UHA; 3 rue Alfred Werner 68057 Mulhouse France
| | - Didier Gigmes
- Aix-Marseille Université, CNRS; Institut de Chimie Radicalaire ICR, UMR 7273; F-13397 Marseille France
| | - Jacques Lalevée
- Institut de Science des Matériaux de Mulhouse IS2 M; UMR CNRS 7361, UHA; 15, rue Jean Starcky 68057 Mulhouse Cedex France
| |
Collapse
|